O21.1 Mycoplasma Genitalium Infectious Load and Treatment Failure Due to Selected Macrolide Resistance. (13th July 2013)

• Record Type: Journal Article
• Authors: Twin, J; Bradshaw, C; Garland, S; Bissessor, M; Chen, M; Walker, J; Fairley, C; Hocking, J; Tabrizi, S
• Is Part Of: Sexually transmitted infections. Volume 89(2013)Supplement 1
• Page Start: A66
• Page End: A67
• Publication Date: 2013-07-13
• Subjects: macrolide resistance -- Mycoplasma genitalium; Sexually transmitted diseases -- Periodicals; HIV infections -- Periodicals; 616.951005
• DOI: 10.1136/sextrans-2013-051184.0203
• Languages: English
• ISSNs: 1368-4973

Abstract

Abstract : Background: Treatment failure due the development of macrolide resistance seen at Melbourne Sexual Health Centre (MSHC) has risen from 15 to 46% over the last six years (p < 0.01). Macrolide resistance is conferred through point mutations in the M. genitalium 23S rRNA gene. Treatment failure with 1g azithromycin is either due to an infection with a pre-existing resistant strain or development of resistance during treatment, but the mechanism is not yet fully understood. Methods: A subset of M. genitalium positive cases seen at MSHC between 2007–9 (n = 67) and 2012 (n = 70) underwent detection of resistance mutations via high resolution melt analysis, with real-time PCR quantifying M. genitalium infectious load. Result: Of those M. genitalium cases that successfully responded to 1g azithromycin, the pre-treatment median loads for 2007–9 (n = 40) and 2012 (n = 48) were 8.5 x 102 and 1.7 x 103 copies per reaction respectively. For M. genitalium strains that possessed resistance in the pre-treatment sample, the loads were remarkably similar to those successfully treated, with 2.2 x 103 copies per reaction detected for 2007–9 (n = 9) and 5.7 x 103 copies for 2012 (n = 22). However, for M. genitalium cases that appeared to develop resistance following treatment, (ie. mutations only detected in follow-up test of cure sample), there was a significantly higher load detected with 3.1 x 104 copies per reaction for 2007–9 (n = 8) and 1.8 x 104 copies for 2012 (n = 8), when compared to either treatment success cases or those with baseline resistance (one sided p < 0.01). Conclusions: The higher infectious load in pre-treatment M. genitalium cases that developed detectable resistance after 1g of azithromycin compared to those with baseline resistance and those cured raises the possibility that heterotypic resistance and/or induced resistance may be contributing to macrolide failure in M. genitalium. These findings have implications for current recommended treatment for M. genitalium.